Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects|
|Author:||La Vincente, S.|
|Citation:||Clinical Pharmacology & Therapeutics, 2008; 83(1):144-152|
|S F La Vincente, J M White, A A Somogyi, F Bochner and C B Chapleo|
|Abstract:||Animal studies have demonstrated that co-administration of an ultra-low-dose opioid antagonist with an opioid agonist may result in enhanced analgesia. Investigation of this effect in humans has been limited and produced inconsistent findings, with previous reports suggesting that dose ratio may be critical to analgesic potentiation. The aim of the current investigation was to determine whether buprenorphine analgesia could be enhanced with the addition of ultra-low-dose naloxone among healthy volunteers, using a range of dose ratios. Tolerance to cold pressor pain was significantly greater with the combination of buprenorphine and naloxone compared to buprenorphine alone, and this effect was dose ratio dependent. Importantly, this enhanced analgesia occurred without an increase in adverse effects; indeed at some ratios, respiratory depression was attenuated. These findings demonstrate that the addition of ultra-low-dose naloxone can enhance the analgesic effect of buprenorphine in humans without a concurrent increase in side effects.|
|Keywords:||Humans; Buprenorphine; Naloxone; Analgesics, Opioid; Narcotic Antagonists; Pain Measurement; Treatment Outcome; Infusions, Intravenous; Double-Blind Method; Pain Threshold; Respiratory Mechanics; Dose-Response Relationship, Drug; Drug Synergism; Pressure; Time Factors; Reference Values; Adult; Female; Male; Cold Temperature|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.